Age (years)
|
38.86
|
6.47
|
38.91
|
5.44
|
Nadir CD4+ (cells/μl)
|
185.02
|
115.79
|
159.99
|
131.80
|
CD4+ T-cell count at baseline (cells/μl)
|
206.75
|
133.53
|
357.88
|
233.05
|
HIV-RNA at baseline (copies/ml)
|
177,480
|
252,619
|
53,615
|
168,410
|
ALT at baseline (x10 IU/l)
|
6.94
|
4.14
|
7.13
|
4.42
|
AST at baseline (x10 IU/l)
|
6.27
|
3.88
|
5.87
|
3.94
|
CD4+ T-cell slope (cells/μl)
|
107.86
|
116.37
|
44.30
|
149.48
|
Exposure to DDX-drugs at baseline (days)
|
-
|
-
|
1,288
|
1,075
|
(qualitative)
|
N
|
%
|
N
|
%
|
Gender (male)
|
113
|
72.90
|
677
|
76.67
|
Risk factor for HIV acquisition (former IVDU)
|
105
|
67.74
|
684
|
77.46
|
HBsAg positivity
|
15
|
10.27
|
55
|
6.48
|
HDVAb positivity
|
4
|
2.96
|
25
|
2.83
|
Previous grade ≥III LFT elevation
|
15
|
9.68
|
317
|
35.90
|
Previous treatment with IFN
|
7
|
4.52
|
72
|
8.15
|
Concurrent use of DDX-drugs
|
50
|
32.26
|
526
|
59.57
|
Concurrent use of 3TC
|
138
|
89.03
|
618
|
69.99
|
Concurrent use of TDF
|
17
|
18.97
|
136
|
15.40
|
Treatment group (Single PI)
|
32
|
20.64
|
202
|
22.88
|
NFV
|
27
|
84.38
|
147
|
72.77
|
IDV
|
2
|
6.25
|
32
|
15.84
|
SQV
|
3
|
9.37
|
19
|
9.41
|
Others
|
-
|
-
|
4
|
1.98
|
Treatment group (Multiple PI)
|
50
|
32.26
|
322
|
36.47
|
LPV/r
|
42
|
84
|
175
|
54.35
|
IDV/r
|
5
|
10
|
83
|
25.78
|
SQV/r
|
1
|
2
|
48
|
14.91
|
Others
|
2
|
4
|
16
|
4.96
|
Treatment group (NNRTI)
|
73
|
47.10
|
359
|
41.62
|
EFV
|
42
|
57.53
|
165
|
45.96
|
NVP
|
31
|
42.47
|
194
|
54.04
|